A randomized, double-blind, placebo-controlled trial of Qidong Bufei Decoction in treating postoperative symptoms of non-small cell lung cancer

Phase 1

Recruiting

• Conditions: non-small cell lung cancer

• Registration Number: ITMCTR2100004896
• Lead Sponsor: Guang'anmen Hospital, China Academy of Chinese Medical Sciences.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Postoperative patients with stage I non-small cell lung cancer diagnosed by pathology or cytology;
2. Enroll in the group within two weeks after thoracoscopy;
3. Aged 18-75 years;
4. Physical condition score ECOG 0-2 points;
5. Estimated survival period >= 6 months;
6. Neutrophils>1.5x10^9/L, platelets > 100x10^9/L, hemoglobin>9.0g/dl; normal bilirubin or < 1.5xULN; AST (SGOT), ALT (SGPT)< 2.5xULN; serum creatinine < 1.5xULN.

Exclusion Criteria

1. Patients who received neoadjuvant chemotherapy before surgery;
2. Those who intend to receive radiotherapy, chemotherapy, targeted drug therapy and other treatment methods within 1 month after surgery;
3. Patients with severe complications such as pulmonary embolism, respiratory failure, and myocardial infarction during the perioperative period;
4. In other clinical trials;
5. Patients during pregnancy or lactation;
6. Patients with a history of mental illness that is difficult to control;
7. Those who are allergic to study drugs;
8. Those who cannot understand and refuse to sign the informed consent form;
9. Those who cannot cooperate with the scale data collector.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
symptom threshold events reduction rate;

Secondary Outcome Measures

Name	Time	Method
quality of life;6 minutes walk test;lung function;mean symptom interference;